Top Headlines: Glaxo Turns Hostile on Human Genome

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

May 9 (Bloomberg) -- GlaxoSmithKline Plc will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S. company, its partner on the Benlysta drug for lupus, rebuffed a takeover approach. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change